Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Capital Expenditures (2020 - 2024)

Olema Pharmaceuticals (OLMA) has 4 years of Capital Expenditures data on record, last reported at $6000.0 in Q2 2024.

  • On a quarterly basis, Capital Expenditures changed N/A to $6000.0 in Q2 2024 year-over-year; TTM through Sep 2025 was $6000.0, a 98.19% decrease, with the full-year FY2024 number at $159000.0, changed N/A from a year prior.
  • Capital Expenditures reached $6000.0 in Q2 2024 per OLMA's latest filing, down from $153000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for OLMA hit a ceiling of $741000.0 in Q2 2021 and a floor of -$10000.0 in Q3 2020.
  • A 4-year average of $153785.7 and a median of $45000.0 in 2020 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 12250.0% in 2021, then tumbled 97.17% in 2022.
  • Tracing OLMA's Capital Expenditures over 4 years: stood at $51000.0 in 2020, then surged by 1270.59% to $699000.0 in 2021, then plummeted by 75.25% to $173000.0 in 2022, then crashed by 96.53% to $6000.0 in 2024.
  • Business Quant data shows Capital Expenditures for OLMA at $6000.0 in Q2 2024, $153000.0 in Q1 2024, and $173000.0 in Q4 2022.